Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Semin Oncol Nurs ; 40(2): 151582, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38290927

ABSTRACT

OBJECTIVES: The goal of this article is to define the role and responsibilities of the oral anticancer medication nurse navigator. METHODS: This article combines findings from a review of scientific literature including research studies, quality improvement projects, case studies, standards, and guidelines combined with the experience and professional insights of the authors in the role creation and function of the oral anticancer medication nurse navigator. RESULTS: The role of the oral anticancer medication nurse navigator includes coordination of patient care, pre-treatment assessment of barriers to adherence, patient and caregiver education, planned follow-up and coaching, and symptom management. Professionally, the role includes the development of interdisciplinary workflows, coordination of care with internal and external stakeholders, clinical staff education, the application of technology, and advocacy. CONCLUSION: The oral anticancer medication nurse navigator uses the nursing process to coordinate care of the individual taking these medications. The role optimizes patient outcomes and benefits the healthcare organization through reduced healthcare costs and the ability to meet accreditation needs. IMPLICATIONS FOR NURSING PRACTICE: The role of the oral anticancer medication nurse navigator provides value to patients taking oral anticancer medications and to the healthcare team.


Subject(s)
Antineoplastic Agents , Nurse's Role , Oncology Nursing , Patient Navigation , Humans , Administration, Oral , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Neoplasms/drug therapy , Neoplasms/nursing , Oncology Nursing/methods
2.
Oncol Nurs Forum ; 49(4): 279-295, 2022 06 17.
Article in English | MEDLINE | ID: mdl-35788731

ABSTRACT

PURPOSE: This evidence-based guideline intends to support patients, clinicians, and others regarding interventions and processes to support patient adherence to oral anticancer medications (OAMs). METHODOLOGIC APPROACH: A panel of healthcare professionals and patient representatives developed a clinical practice guideline to support patients taking OAMs. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology and criteria for trustworthy guidelines were followed. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. A quantitative or narrative synthesis of the evidence was completed. Certainty of the evidence was assessed using GRADE. FINDINGS: The panel agreed on recommendations and suggested an adherence risk assessment, education addressing adherence, ongoing assessment, proactive follow-up, coaching, and motivational interviewing in addition to usual care. The panel suggested the implementation of a structured OAM program. IMPLICATIONS FOR NURSING: As cancer treatment shifts from clinic to home settings, interventions and programs to support patients on OAMs are needed.


Subject(s)
Patient Compliance , Humans
3.
J Clin Oncol ; 38(6): 633-644, 2020 02 20.
Article in English | MEDLINE | ID: mdl-31815576

ABSTRACT

PURPOSE: To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications. METHODS: An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delivery of oral anticancer and supportive care drugs was performed to April 2019 using PubMed and Google Scholar. Available patient-centered standards, including one previously developed by the National Community Oncology Dispensing Association (NCODA), were considered for endorsement. Public comments were solicited and considered in preparation of the final manuscript. RESULTS: A high-quality systematic review that was current to May 2016 was adopted into the evidence base. Five additional primary studies of multifaceted interventions met the inclusion criteria. These studies generally included a multicomponent intervention, often led by an oncology pharmacist, and also included patient education and regular follow-up and monitoring. These interventions resulted in significant improvements to patient quality and safety and demonstrated improvements in adherence and other patient outcomes. CONCLUSION: The findings of the systematic review were consistent with the NCODA patient-centered standards for patient relationships and education, adherence, safety, collection of data, documentation, and other areas. NCODA standards were adopted and used as basis for these American Society of Clinical Oncology/NCODA standards. Additional information is available at www.asco.org/mid-standards.


Subject(s)
Antineoplastic Agents , Medical Oncology/standards , Patient-Centered Care/standards , Practice Patterns, Physicians'/standards , Prescription Drugs/standards , Humans
4.
Genome Biol ; 4(5): R32, 2003.
Article in English | MEDLINE | ID: mdl-12734012

ABSTRACT

We have developed a unique methodology for the combined analysis of histomorphometric and gene-expression profiles amenable to intensive data mining and multisample comparison for a comprehensive approach to toxicology. This hybrid technology, termed extensible morphometric relational gene-expression analysis (EMeRGE), is applied in a toxicological study of time-varied vehicle- and carbon-tetrachloride (CCl4)-treated rats, and demonstrates correlations between specific genes and tissue structures that can augment interpretation of biological observations and diagnosis.


Subject(s)
Gene Expression Profiling , Toxicology/methods , Animals , Carbon Tetrachloride/toxicity , Chemical and Drug Induced Liver Injury , Data Interpretation, Statistical , Histocytochemistry/methods , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver Diseases/genetics , Liver Diseases/pathology , Oligonucleotide Array Sequence Analysis/methods , RNA/genetics , RNA/metabolism , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...